Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 4/20 | 0.59 |
| ▸ | JAK1 | P23458 | 3/20 | 0.59 |
| ▸ | TYK2 | P29597 | 3/20 | 0.59 |
| ▸ | JAK3 | P52333 | 3/20 | 0.59 |
| ▸ | MAP4K3 | Q8IVH8 | 5/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.54 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.54 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.54 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.52 |
| ▸ | GRK5 | P34947 | 5/20 | 0.50 |
| ▸ | GRK2 | P25098 | 4/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.49 |
| ▸ | MET | P08581 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1425297 | 0.91 | JAK2 (0.54) | JAK2JAK1TYK2JAK3MAP4K3 | |
| SCHEMBL28802167 | 0.91 | MAP4K3 (0.55) | JAK2JAK1TYK2JAK3MAP4K3 | |
| SCHEMBL986491 | 0.89 | NTRK1 (0.54) | JAK2JAK1TYK2JAK3MAP4K3 | |
| SCHEMBL12538512 | 0.89 | JAK2 (0.52) | JAK2JAK1TYK2JAK3MAP4K3 | |
| SCHEMBL12539061 | 0.88 | FGFR3 (0.55) | JAK2JAK1TYK2JAK3MAP4K3 | |
| SCHEMBL986517 | 0.88 | ALK (0.56) | JAK2JAK1TYK2JAK3MAP4K3 | |
| SCHEMBL12538870 | 0.87 | JAK2 (0.49) | JAK2JAK1TYK2JAK3MAP4K3 | |
| SCHEMBL12538552 | 0.87 | JAK2 (0.49) | JAK2JAK1TYK2JAK3MAP4K3 | |
| SCHEMBL12539055 | 0.87 | FGFR1 (0.57) | JAK2JAK1TYK2JAK3MAP4K3 | |
| SCHEMBL27900706 | 0.87 | FGFR3 (0.55) | JAK2JAK1TYK2JAK3MAP4K3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232406-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-31 | — | — | US | claimed |
| US-20110059936-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | claimed |
| US-7872031-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-18 | — | — | US | claimed |
| EP-2004625-B1 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMA (US) | 2009-12-30 | — | — | EP | claimed |
| US-20070254868-A1 | C-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | claimed |
| US-8232406-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232406-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-31 | — | — | US | disclosed |
| US-20110059936-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | disclosed |
| US-20110059936-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | disclosed |
| US-7872031-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-18 | — | — | US | disclosed |
| US-7872031-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-18 | — | — | US | disclosed |
| EP-2004625-B1 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMA (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20070254868-A1 | C-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254868-A1 | C-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | disclosed |
| WO-2007111904-A2 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059936-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, ABL1 | JAK2 33/4885JAK1 133/4885TYK2 948/4885 |
| US-20070254868-A1 | C-MET protein kinase inhibitors | MET, PRKCH, ABL1 | JAK2 33/4885JAK1 133/4885TYK2 948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.